Suppr超能文献

轮状病毒免疫接种:全球覆盖情况及实施过程中的地方障碍

Rotavirus immunization: Global coverage and local barriers for implementation.

作者信息

Lo Vecchio Andrea, Liguoro Ilaria, Dias Jorge Amil, Berkley James A, Boey Chris, Cohen Mitchell B, Cruchet Sylvia, Salazar-Lindo Eduardo, Podder Samir, Sandhu Bhupinder, Sherman Philip M, Shimizu Toshiaki, Guarino Alfredo

机构信息

Section of Pediatrics, Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.

Department of Clinical and Experimental Medical Sciences, University Hospital of Udine, Udine, Italy.

出版信息

Vaccine. 2017 Mar 14;35(12):1637-1644. doi: 10.1016/j.vaccine.2017.01.082. Epub 2017 Feb 16.

Abstract

BACKGROUND

Rotavirus (RV) is a major agent of gastroenteritis and an important cause of child death worldwide. Immunization (RVI) has been available since 2006, and the Federation of International Societies of Gastroenterology Hepatology and Nutrition (FISPGHAN) identified RVI as a top priority for the control of diarrheal illness. A FISPGHAN working group on acute diarrhea aimed at estimating the current RVI coverage worldwide and identifying barriers to implementation at local level.

METHODS

A survey was distributed to national experts in infectious diseases and health-care authorities (March 2015-April 2016), collecting information on local recommendations, costs and perception of barriers for implementation.

RESULTS

Forty-nine of the 79 contacted countries (62% response rate) provided a complete analyzable data. RVI was recommended in 27/49 countries (55%). Although five countries have recommended RVI since 2006, a large number (16, 33%) included RVI in a National Immunization Schedule between 2012 and 2014. The costs of vaccination are covered by the government (39%), by the GAVI Alliance (10%) or public and private insurance (8%) in some countries. However, in most cases, immunization is paid by families (43%). Elevated cost of vaccine (49%) is the main barrier for implementation of RVI. High costs of vaccination (rs=-0.39, p=0.02) and coverage of expenses by families (rs=0.5, p=0.002) significantly correlate with a lower immunization rate. Limited perception of RV illness severity by the families (47%), public-health authorities (37%) or physicians (24%) and the timing of administration (16%) are further major barriers to large- scale RVI programs.

CONCLUSIONS

After 10years since its introduction, the implementation of RVI is still unacceptably low and should remain a major target for global public health. Barriers to implementation vary according to setting. Nevertheless, public health authorities should promote education for caregivers and health-care providers and interact with local health authorities in order to implement RVI.

摘要

背景

轮状病毒(RV)是全球范围内引起肠胃炎的主要病原体,也是儿童死亡的重要原因。自2006年以来已有轮状病毒免疫接种(RVI)可用,国际胃肠病学、肝病学和营养学会联合会(FISPGHAN)将RVI确定为控制腹泻病的首要任务。一个FISPGHAN急性腹泻工作组旨在评估全球当前的RVI覆盖率,并确定地方层面实施过程中的障碍。

方法

向各国传染病专家和卫生保健当局发放了一份调查问卷(2015年3月至2016年4月),收集有关地方建议、成本以及对实施障碍的看法等信息。

结果

79个被联系国家中的49个(回复率62%)提供了完整的可分析数据。49个国家中的27个(55%)推荐了RVI。虽然有5个国家自2006年以来就推荐了RVI,但大量国家(16个,33%)在2012年至2014年期间将RVI纳入了国家免疫规划。在一些国家,疫苗接种费用由政府承担(39%)、由全球疫苗免疫联盟承担(10%)或由公共和私人保险承担(8%)。然而,在大多数情况下,免疫接种费用由家庭支付(43%)。疫苗成本高昂(49%)是实施RVI的主要障碍。疫苗接种费用高昂(rs=-0.39,p=0.02)以及家庭承担费用(rs=0.5,p=0.002)与较低的免疫接种率显著相关。家庭(47%)、公共卫生当局(37%)或医生(24%)对RV疾病严重程度的认识有限以及接种时间(16%)是大规模RVI项目的进一步主要障碍。

结论

RVI引入10年后,其实施率仍然低得令人无法接受,应继续作为全球公共卫生的主要目标。实施障碍因环境而异。尽管如此,公共卫生当局应促进对护理人员和卫生保健提供者的教育,并与地方卫生当局互动,以实施RVI。

相似文献

1
Rotavirus immunization: Global coverage and local barriers for implementation.
Vaccine. 2017 Mar 14;35(12):1637-1644. doi: 10.1016/j.vaccine.2017.01.082. Epub 2017 Feb 16.
2
A review of rotavirus vaccine use in Asia and the Pacific regions: challenges and future prospects.
Expert Rev Vaccines. 2021 Dec;20(12):1499-1514. doi: 10.1080/14760584.2020.1853532. Epub 2021 Apr 20.
3
Global rotavirus vaccine introductions and coverage: 2006 - 2016.
Hum Vaccin Immunother. 2018;14(9):2281-2296. doi: 10.1080/21645515.2018.1470725. Epub 2018 Jun 18.
5
Mucosal Immunity and acute viral gastroenteritis.
Hum Vaccin Immunother. 2014;10(7):2112-4. doi: 10.4161/hv.29605.
6
Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Vaccine. 2015 May 7;33 Suppl 1:A109-18. doi: 10.1016/j.vaccine.2014.12.079.
7
Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Vaccine. 2013 Dec 9;31(51):6072-8. doi: 10.1016/j.vaccine.2013.10.022. Epub 2013 Oct 29.
8
Effectiveness of Pentavalent Rotavirus Vaccine Under Conditions of Routine Use in Rwanda.
Clin Infect Dis. 2016 May 1;62 Suppl 2(Suppl 2):S208-12. doi: 10.1093/cid/civ1016.
9
Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031.
Vaccine. 2018 Nov 12;36(47):7215-7221. doi: 10.1016/j.vaccine.2017.11.080. Epub 2017 Dec 6.
10
Rotavirus vaccination rate disparities seen among infants with acute gastroenteritis in Georgia.
Ethn Health. 2017 Dec;22(6):585-595. doi: 10.1080/13557858.2016.1244744. Epub 2016 Oct 14.

引用本文的文献

1
Unlocking the power of probiotics, postbiotics: targeting apoptosis for the treatment and prevention of digestive diseases.
Front Nutr. 2025 Mar 31;12:1570268. doi: 10.3389/fnut.2025.1570268. eCollection 2025.
2
Acute Infectious Diarrhea.
Adv Exp Med Biol. 2024;1449:143-156. doi: 10.1007/978-3-031-58572-2_9.
3
Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule.
Hum Vaccin Immunother. 2022 Nov 30;18(6):2139097. doi: 10.1080/21645515.2022.2139097. Epub 2022 Nov 21.
6
Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections.
Microorganisms. 2021 Jul 27;9(8):1599. doi: 10.3390/microorganisms9081599.
7
Effect of childhood rotavirus vaccination on community rotavirus prevalence in rural Ecuador, 2008-13.
Int J Epidemiol. 2020 Oct 1;49(5):1691-1701. doi: 10.1093/ije/dyaa124.
8
Acute Gastroenteritis in Children of the World: What Needs to Be Done?
J Pediatr Gastroenterol Nutr. 2020 May;70(5):694-701. doi: 10.1097/MPG.0000000000002669.
9
Gene-edited vero cells as rotavirus vaccine substrates.
Vaccine X. 2019 Oct 8;3:100045. doi: 10.1016/j.jvacx.2019.100045. eCollection 2019 Dec 10.
10
Role of healthcare practitioners in rotavirus disease awareness and vaccination - insights from a survey among caregivers.
Hum Vaccin Immunother. 2020;16(1):138-147. doi: 10.1080/21645515.2019.1632685. Epub 2019 Jul 16.

本文引用的文献

1
Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014.
Euro Surveill. 2016 Jul 7;21(27). doi: 10.2807/1560-7917.ES.2016.21.27.30273.
4
Rotavirus vaccination in Europe: drivers and barriers.
Lancet Infect Dis. 2014 May;14(5):416-25. doi: 10.1016/S1473-3099(14)70035-0.
7
Indicators to assess National Immunization Technical Advisory Groups (NITAGs).
Vaccine. 2013 May 28;31(23):2653-7. doi: 10.1016/j.vaccine.2013.01.047. Epub 2013 Feb 8.
10
Acute gastroenteritis disease: Report of the FISPGHAN Working Group.
J Pediatr Gastroenterol Nutr. 2012 Nov;55(5):621-6. doi: 10.1097/MPG.0b013e318272b5e2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验